The Virginia Tech Board of Visitors is scheduled to vote next week on a proposal that could add up to $229.2 million to the ...
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback